Cargando…

Circulating Anti-GB3 Antibody as a Biomarker of Myocardial Inflammation in Patients with Fabry Disease Cardiomyopathy

Background: Fabry disease cardiomyopathy (FDCM) has manifested some resistance to enzyme replacement therapy (ERT), particularly in its advanced phase. Recently, myocardial inflammation of autoimmune origin has been demonstrated in FDCM. Aims: The objective of this study was the assessment of circul...

Descripción completa

Detalles Bibliográficos
Autores principales:	Frustaci, Andrea, Verardo, Romina, Magnocavallo, Michele, Scialla, Rossella, Sansone, Luigi, Russo, Matteo Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10299309/ https://www.ncbi.nlm.nih.gov/pubmed/37373761 http://dx.doi.org/10.3390/jcm12124068

Ejemplares similares

Hypertrophic obstructive cardiomyopathy caused by Fabry disease: implications for surgical myectomy
por: Frustaci, Andrea, et al.
Publicado: (2023)

Downregulation of Mannose-6-Phosphate Receptors in Fabry Disease Cardiomyopathy: A Potential Target for Enzyme Therapy Enhancement
por: Frustaci, Andrea, et al.
Publicado: (2022)

Fabry cardiomyopathy: Gb3‐induced auto‐reactive panmyocarditis requiring heart transplantation
por: Frustaci, Andrea, et al.
Publicado: (2020)

Pemphigus‐associated cardiomyopathy: report of autoimmune myocarditis and review of literature
por: Frustaci, Andrea, et al.
Publicado: (2021)

Immune‐Mediated Myocarditis in Fabry Disease Cardiomyopathy
por: Frustaci, Andrea, et al.
Publicado: (2018)

Myocardial Aldosterone Receptor and Aquaporin 1 Up-Regulation Is Associated with Cardiomyocyte Remodeling in Human Heart Failure
por: Frustaci, Andrea, et al.
Publicado: (2021)

Hypertrophy of unaffected cardiomyocytes correlates with severity of cardiomyopathy in female patients with Fabry disease
por: Chimenti, Cristina, et al.
Publicado: (2021)

Removal of cardiac AL amyloid with positive remodelling of cardiomyocytes and of restrictive cardiomyopathy
por: Frustaci, Andrea, et al.
Publicado: (2022)

Divergent Impact of Enzyme Replacement Therapy on Human Cardiomyocytes and Enterocytes Affected by Fabry Disease: Correlation with Mannose-6-phosphate Receptor Expression
por: Frustaci, Andrea, et al.
Publicado: (2022)

Novel dilated cardiomyopathy associated to Calreticulin and Myo7A gene mutation in Usher syndrome
por: Frustaci, Andrea, et al.
Publicado: (2021)

Prelamin A mediates myocardial inflammation in dilated and HIV-associated cardiomyopathies
por: Brayson, Daniel, et al.
Publicado: (2019)

Hypersensitivity Myocarditis after COVID-19 mRNA Vaccination
por: Frustaci, Andrea, et al.
Publicado: (2022)

Interleukin-17A-Correlated Myocarditis in Patients with Psoriasis: Cardiac Recovery following Secukinumab Administration
por: Frustaci, Andrea, et al.
Publicado: (2023)

Inflammation of Conduction Tissue in Patients with Arrhythmic Phenotype of Myocarditis
por: Frustaci, Andrea, et al.
Publicado: (2020)

Biopsy-proven autoimmune myocarditis in HIV-associated dilated cardiomyopathy
por: Frustaci, Andrea, et al.
Publicado: (2014)

Mutations in the GLA Gene and LysoGb3: Is It Really Anderson-Fabry Disease?
por: Duro, Giovanni, et al.
Publicado: (2018)

Migalastat HCl Reduces Globotriaosylsphingosine (Lyso-Gb(3)) in Fabry Transgenic Mice and in the Plasma of Fabry Patients
por: Young-Gqamana, Brandy, et al.
Publicado: (2013)

Fabry Cardiomyopathy
por: Yoon, Jae Yong, et al.
Publicado: (2013)

False‐positive bone scintigraphy denoting transthyretin amyloid in elderly hypertrophic cardiomyopathy
por: Chimenti, Cristina, et al.
Publicado: (2021)

Novel Genetic Microvascular Dysplasia Causing Hypoperfusion of Cardiac, Renal, and Cerebral Circulation
por: Frustaci, Andrea, et al.
Publicado: (2023)

Hypoxia and Inflammation as a Consequence of β-Fibril Accumulation: A Perspective View for New Potential Therapeutic Targets
por: Russo, Matteo A., et al.
Publicado: (2019)

Cardiac and skeletal myopathy in Fabry disease: a clinicopathologic correlative study()()
por: Chimenti, Cristina, et al.
Publicado: (2012)

Cardiomyopathies and Adrenal Diseases
por: Petramala, Luigi, et al.
Publicado: (2020)

Cardiac abnormalities in Anderson-Fabry disease and Fabry’s cardiomyopathy
por: Morrissey, Ryan P, et al.
Publicado: (2011)

Lyso-Gb3 associates with adverse long-term outcome in patients with Fabry disease
por: Nowak, Albina, et al.
Publicado: (2022)

Elucidating the toxic effect and disease mechanisms associated with Lyso-Gb3 in Fabry disease
por: Nikolaenko, Valeria, et al.
Publicado: (2023)

Infiltration of Conduction Tissue Is a Major Cause of Electrical Instability in Cardiac Amyloidosis
por: Frustaci, Andrea, et al.
Publicado: (2023)

A Case of Fabry Cardiomyopathy
por: Nah, Jong Chun, et al.
Publicado: (2009)

Biomarkers of Myocardial Fibrosis: Revealing the Natural History of Fibrogenesis in Fabry Disease Cardiomyopathy
por: Aguiar, Patrício, et al.
Publicado: (2018)

Immunosuppressive therapy in virus-negative inflammatory cardiomyopathy: 20-year follow-up of the TIMIC trial( )
por: Chimenti, Cristina, et al.
Publicado: (2022)

Circulated TGF-β1 and VEGF-A as Biomarkers for Fabry Disease-Associated Cardiomyopathy
por: Ivanova, Margarita M., et al.
Publicado: (2023)

A Liquid Chromatography-Quadrupole-Time-of-Flight Mass Spectrometric Assay for the Quantification of Fabry Disease Biomarker Globotriaosylceramide (GB3) in Fabry Model Mouse
por: Shin, Seok-Ho, et al.
Publicado: (2018)

Infarct‐like myocarditis with coronary vasculitis and aneurysm formation caused by Epstein–Barr virus infection
por: Chimenti, Cristina, et al.
Publicado: (2020)

Virus-Negative Necrotizing Coronary Vasculitis with Aneurysm Formation in Human SARS-CoV-2 Infection
por: Frustaci, Andrea, et al.
Publicado: (2021)

A proposed strategy for anticoagulation therapy in noncompaction cardiomyopathy
por: Chimenti, Cristina, et al.
Publicado: (2021)

Long-Term Effect of Antibodies against Infused Alpha-Galactosidase A in Fabry Disease on Plasma and Urinary (lyso)Gb3 Reduction and Treatment Outcome
por: Rombach, Saskia M., et al.
Publicado: (2012)

Assessment of plasma lyso-Gb(3) for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease
por: Bichet, Daniel G., et al.
Publicado: (2020)

Role of cardiac imaging in Anderson-Fabry cardiomyopathy
por: Serra, Walter, et al.
Publicado: (2019)

Fabry Cardiomyopathy: Current Practice and Future Directions
por: Yim, Jeffrey, et al.
Publicado: (2021)

Fabry Cardiomyopathy: Current Treatment and Future Options
por: Vardarli, Irfan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9fg9krlo6vfme889nr2p081lb7